Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
Cybin Inc. (symbol: CYBN) is a pioneering biopharmaceutical company dedicated to addressing mental health challenges through innovative therapeutics. Specializing in psychedelic-based therapies, Cybin focuses on developing novel compounds, delivery mechanisms, and protocols aimed at treating a range of psychiatric and neurological conditions.
Cybin's core business revolves around advancing clinical-stage programs designed to harness the potential of psychedelics. The company is engaged in creating safe and effective treatments for conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD). Their research and development efforts highlight the transformative potential of these therapies in modern medicine.
Recently, Cybin has achieved significant milestones, including progress in their proprietary drug delivery technologies. These advancements aim to improve the administration and efficacy of psychedelic compounds, ensuring patients receive the maximum therapeutic benefit. Their innovative approach extends to developing new chemical entities (NCEs) that hold promise in the field of mental health treatment.
Financially, Cybin remains robust and committed to its growth strategy. The company has secured strategic partnerships and collaborations that bolster its research initiatives and clinical trials. These alliances are crucial in accelerating the development and commercialization of their therapeutic solutions.
Cybin's product pipeline is impressive, featuring multiple candidates in various stages of development. These include CYB001, a formulation targeting major depressive disorder, and CYB003, designed for anxiety disorders. Each product undergoes rigorous testing to ensure safety and effectiveness.
In summary, Cybin Inc. is at the forefront of revolutionizing mental health treatment through psychedelic-based therapies. Their dedication to advancing science and addressing unmet medical needs positions them as a significant player in the biopharmaceutical industry.
Cybin Inc. (NYSE American:CYBN) announced its participation in the 2024 Milken Institute Future of Health Summit. CEO Doug Drysdale will speak on a panel titled 'The Next Frontier in Mental Health Research' on November 13, 2024, in Washington DC.
The discussion will focus on novel approaches to mental health treatments. Drysdale will share updates on Cybin's clinical advancements, including CYB003, their deuterated psilocin program for major depressive disorder entering Phase 3, and CYB004, their deuterated DMT program in Phase 2 for generalized anxiety disorder.
The panel will address mental illness, which affects one in eight people globally, exploring new therapeutic approaches and personalized treatment solutions.
Cybin has been granted U.S. patent 12,122,741 by the USPTO for composition of matter claims related to its CYB005 phenethylamines program. The company is investigating these novel molecules at non-hallucinogenic doses for various Central Nervous System disorders. The development includes exploring non-hallucinogenic neuroplastogens and targeted serotonin 5-HT1A and 5-HT2C receptor agonists. This addition brings Cybin's intellectual property portfolio to over 70 granted patents and more than 220 pending patent applications.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage neuropsychiatry company, has announced its participation in the Water Tower Research Fireside Chat Series on October 8, 2024, at 3:00 p.m. ET. The event will feature Doug Drysdale, Cybin's CEO, in a discussion hosted by Robert Sassoon, Senior Research Analyst at Water Tower Research.
The fireside chat will cover key topics including:
- Cybin's lead development programs CYB003 and CYB004 and upcoming clinical milestones
- Differentiators in Cybin's development approach compared to other neuropsychiatric developments
- Lessons learned and applied from the FDA's Lykos NDA rejection
Interested parties can register for the webcast through a provided link. An archived version of the webcast will be available on Cybin's investor relations website after the event.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) has expanded its clinical team to support the upcoming Phase 3 pivotal program for CYB003 in Major Depressive Disorder (MDD). Key appointments include:
- Dr. Mirza Rahman as Senior VP, Patient Safety & Pharmacovigilance
- Dr. Marcelo Gutierrez as VP, Clinical Pharmacology
- Dr. Atul R. Mahableshwarkar as program lead for CYB003
- Dr. Tom Macek as program lead for CYB004
The strengthened team will support CYB003 pivotal trials, consisting of three studies spanning up to 12 countries. These additions bring expertise in patient safety, pharmacovigilance, clinical pharmacology, and drug development, important for advancing Cybin's proprietary deuterated psilocin program for adjunctive treatment of MDD.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough neuropsychiatry company, has announced its participation in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit. The virtual event will take place on September 26, 2024.
Amir Inamdar, Cybin's Chief Medical Officer, will be part of a panel discussion titled 'Advancement in Psychedelic Therapies for Neuropsychiatry'. The panel will be webcast live on Thursday, September 26, 2024, at 10:00 a.m. ET.
Interested parties can access the webcast through a provided link. An archived version of the webcast will also be available on Cybin's investor relations website under the Events & Presentations page.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage neuropsychiatry company, provided updates on its key clinical programs. The company is preparing to initiate a pivotal Phase 3 study for CYB003, its deuterated psilocin program for Major Depressive Disorder (MDD), which has received FDA Breakthrough Therapy Designation. Cybin expects to report 12-month efficacy data from the Phase 2 study of CYB003 in early Q4 2024.
For CYB004, Cybin's deuterated dimethyltryptamine program for Generalized Anxiety Disorder (GAD), the company anticipates Phase 2 topline efficacy and safety results by year-end 2024 or early Q1 2025. Cybin has also strengthened its R&D team with the addition of Dr. Atul R. Mahableshwarkar and Dr. Tom Macek as program leads for CYB003 and CYB004, respectively.
Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN), a clinical-stage neuropsychiatry company, has completed a share consolidation on a 38:1 basis. The consolidation, effective immediately, reduces the company's outstanding common shares from 759,692,495 to approximately 19,991,907. Trading of the consolidated shares begins today. This move does not affect shareholders' ownership percentages or voting power, except for minor adjustments due to fractional shares. The company has also adjusted the exercise price and number of shares issuable for outstanding warrants and options in line with the consolidation ratio.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough neuropsychiatry company, announces its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024 in New York, NY. CEO Doug Drysdale will engage in a fireside chat on Monday, September 9, 2024, at 8:30 a.m. ET, which will be webcast live and later archived on the company's investor relations website.
Additionally, Drysdale will join a panel discussion titled "Psychedelics in Psychiatry: Breaking New Ground in Mood Disorders" on Tuesday, September 10, 2024, at 3:00 p.m. ET. This event highlights Cybin's commitment to developing innovative next-generation treatment options for mental healthcare.
Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) held its annual and special meeting of shareholders on August 27, 2024, with 59.66% of total issued and outstanding common shares represented. Key outcomes include:
1. Appointment of Zeifmans LLP as auditor
2. Election of seven directors
3. Approval of common share consolidation
4. Amendments to equity incentive plan, shareholder rights plan, and common share purchase warrants
The company announced a 38:1 share consolidation, reducing outstanding shares from 759,692,495 to approximately 19,991,907. This consolidation is expected to be effective around September 19, 2024, subject to CBOE Canada approval.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) has announced plans to initiate a Phase 3 pivotal trial of CYB003 for the adjunctive treatment of Major Depressive Disorder (MDD) in late summer 2024. This follows a successful Type B Initial Breakthrough Therapy Meeting with the FDA. The trial will include 30 clinical sites across the United States and Europe. Cybin's Phase 2 study showed promising results, with 75% of patients in remission from depression four months after two 16mg doses of CYB003. The company plans to implement measures to mitigate functional unblinding risks in the pivotal study, including a three-arm design and the use of remote, independent, blinded raters. Cybin expects to report 12-month efficacy data from the Phase 2 study in Q4 2024.
FAQ
What is the current stock price of Cybin (CYBN)?
What is the market cap of Cybin (CYBN)?
What is Cybin Inc.?
What does Cybin Inc. specialize in?
What are the core areas of Cybin's research?
What recent achievements has Cybin Inc. made?
Can you name some of Cybin's product candidates?
How does Cybin contribute to mental health treatment?
Has Cybin formed any strategic partnerships?
What is the significance of Cybin's drug delivery technologies?
What conditions are Cybin's therapies aimed at treating?
Where can I find the latest news about Cybin Inc.?
